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ABSTRACT
Bisphosphonates are effective antiresorptive agents owing to their bone-targeting property and ability to inhibit osteoclasts. It remains
unclear, however, whether any non-osteoclast cells are directly affected by these drugs in vivo. Two fluorescent risedronate analogues,
carboxyfluorescein-labeled risedronate (FAM-RIS) and Alexa Fluor 647–labeled risedronate (AF647-RIS), were used to address this
question. Twenty-four hours after injection into 3-month-old mice, fluorescent risedronate analogues were bound to bone surfaces.
More detailed analysis revealed labeling of vascular channel walls within cortical bone. Furthermore, fluorescent risedronate analogues
were present in osteocytic lacunae in close proximity to vascular channels and localized to the lacunae of newly embedded osteocytes
close to the bone surface. Following injection into newborn rabbits, intracellular uptake of fluorescently labeled risedronate was
detected in osteoclasts, and the active analogue FAM-RIS caused accumulation of unprenylated Rap1A in these cells. In addition,
CD14
high bone marrow monocytes showed relatively high levels of uptake of fluorescently labeled risedronate, which correlated with
selective accumulation of unprenylated Rap1A in CD14
þ cells, as well as osteoclasts, following treatment with risedronate in vivo. Similar
results were obtained when either rabbit or human bone marrow cells were treated with fluorescent risedronate analogues in vitro.
These findings suggest that the capacity of different cell types to endocytose bisphosphonate is a major determinant for the degree of
cellular drug uptake in vitro as well as in vivo. In conclusion, this study shows that in addition to bone-resorbing osteoclasts,
bisphosphonates may exert direct effects on bone marrow monocytes in vivo.  2010 American Society for Bone and Mineral Research.
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Introduction
B
isphosphonates (BPs) are antiresorptive drugs that are used
widely in the treatment of bone diseases involving excessive
osteoclastic resorption.
(1) Owing to their two phosphonate
groups, BPs bind to bone mineral and are internalized by
osteoclasts during the resorption process.
(2) Nitrogen-containing
BPs (N-BPs), such as risedronate (RIS), disrupt osteoclast function
by inhibiting the enzyme farnesyl pyrophosphate (FPP)
synthase.
(3,4) This causes a depletion of intracellular isoprenoid
lipids required for the prenylation of proteins, such as small
GTPases, resulting in the accumulation of unprenylated proteins
with defective function within the cell.
(5,6)
The exact localization of BP within bone, as well as the ability
of cells other than osteoclasts to take up BP in vivo, remains
unclear.PreviousstudieshaveusedradiolabeledBPstostudythe
localization and cellular uptake of BP in animal models.
(7–9)
Intracellular uptake of [
3H]alendronate ([
3H]ALN) was detected in
osteoclasts but not any other cells in histologic sections of
femora from newborn rats following administration of 0.4mg/kg
[
3H]ALN.
(7) More recently, we and others have developed
fluorescent BP analogues to study the localization and cellular
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606uptake of these drugs in more detail. A comparison between
Alexa Fluor 488-ALN and [
14C]zoledronate revealed that these
compounds have an identical mechanism of cellular uptake that
largely depends on fluid-phase endocytosis,
(10) demonstrating
that fluorescent BP analogues are useful tools with which to
study cellular uptake of BP. More recently, we have used
fluorescein-ALN to evaluate intracellular uptake of BP in vitro
under a variety of cell culture conditions, demonstrating that
fluorescein-ALN binds avidly to bone mineral in vitro and that
only osteoclasts efficiently internalize BP from the bone surface
during resorption.
(2)
Despitetheseobservations, it hasbecome clearinrecentyears
that other cell types may be affected by BPs in vivo. Numerous
studies have suggested that effects on tumor cells or endothelial
cells may explain the antitumor activity of these drugs in animal
models of cancer.
(11) In addition, in vitro studies have suggested
that effects on circulating monocytes and subsequent activation
of peripheral blood Vg9Vd2 T cells are responsible for the
development of an acute-phase response commonly observed
inpatients receiving intravenous N-BP administration for the first
time.
(12–16) It is still unclear, however, which cell types are able to
internalize BP and thus are likely to be directly affected by these
drugs in vivo.
Zaheer and colleagues recently described a novel purified
fluorescent BP analogue, IRDye78-labeled pamidronate,
(17) and
the near-infrared analogues of pamidronate Osteosense680 and
Osteosense750 have been evaluated recently for their potential
as optical markers of bone metabolism.
(18) However, no detailed
histologic analysis of localization or assessment of intracellular
uptake of these fluorescent BP analogues in vivo has been
reported.
We have recently developed a novel method for the synthesis
of stable and highly purified fluorescent RIS analogues, including
a carboxyfluorescein conjugate (FAM-RIS) that retains the ability
of the parent BP to inhibit protein prenylation in cells.
(19) In this
study, we used both FAM-RIS and Alexa Fluor 647–labeled RIS
(AF647-RIS) to investigate in more detail the localization and
cellular uptake of BP in vivo.
Materials and Methods
Synthesis and purification of fluorescent RIS analogues
RIS was provided by Procter & Gamble Pharmaceuticals (Mason,
OH, USA). Fluoresceins and AF647 were purchased from Invitrogen
(Paisley, UK). FAM-RIS was synthesized by stable conjugation of
5(6)-carboxyfluorescein [5(6)-FAM] or its pure isomers 5-FAM or 6-
FAM via its succinimidyl ester to the pyridine nitrogen of RIS via a
novel linker strategy and highly purified, as described pre-
viously.
(19) AF647-RIS was synthesized similarly. Drugs were
dissolved in PBS.
Constant composition kinetic studies of crystal growth
Constant composition (CC) hydroxyapatite (HAP) growth
experiments were performed as described previously
(20) in the
presence of 1.0mM BP. Carbonated hydroxyapatite (CAP),
prepared by direct precipitation from solution,
(21) was used as
seed material; CAP crystals contained 7.96% carbonate by mass,
as determined by carbon coulometry.
Treatment of animals
All animal studies were approved by the Home Office (UK) and
conducted in accordance with the Animals (Scientific Proce-
dures) Act of 1986 and the Home Office Code of Practice. To
study the localization of BP in vivo, 3month old C57Bl/6 or MF1
micereceivedsinglesubcutaneousinjectionswith0.2to1mg/kg
FAM-RIS (molecular weight 714g/mol) or 0.9mg/kg AF647-RIS
(molecular weight 1198g/mol). To study cellular uptake in vivo,
newborn(3dayold)NewZealand Whiterabbitsreceivedasingle
subcutaneous injection with 0.5 or 3mg/kg FAM-RIS, 0.9mg/kg
AF647-RIS, or 1.2 or 5mg/kg RIS. As controls, animals received a
subcutaneous injection of vehicle only, or 0.5mg/kg unconju-
gated fluorescein (Sigma Chemical Co., St. Louis, MO, USA).
Twenty-four hours or 7 days later, animals were sacrificed and
tissues collected.
Detection of AF647-RIS in whole tissues
Bones and soft tissue organs (kidneys, liver, spleen) of 3month
old female MF1 mice subcutaneously injected with AF647-RIS
(0.9mg/kg) or vehicle were excised either 1 or 7 days after
injection. Following fixation, bones and organs were scanned
on a LI-COR Odyssey Infrared Imager (LI-COR Biosciences,
Cambridge, UK) using the 680nm laser to detect AF647-RIS.
Histologic analysis
Mouse tibiae or rabbit ulnae were fixed in 4% formaldehyde
and embedded in methyl methacrylate and cut in half either
longitudinally or cross-sectionally through the midshaft.
Polished block surfaces either were analyzed directly or
sections were cut (2 mm section thickness) using a diamond
knife. Sections were counterstained with the nuclear dye
TO-PRO-3and/or wheatgerm-agglutinin-Alexa Fluor 594
(Invitrogen) and mounted using Vectashield (Vector Labs,
Peterborough, UK) or ProLong Gold (Invitrogen). Blocks and
sections wereanalyzed using aZeissLSM510META system and
AIM software or, for acquisition of tile scans to generate high-
magnification overview images, on a Zeiss LSM710 META
systemwithZENsoftware(CarlZeiss,Ltd.,WelwynGardenCity,
UK). For quantification of AF647-RIS labeling of osteocyte
lacunar walls, the cortices in cross sections of tibiae from four
different mice were analyzed. At least three images of different
regions throughout the corticalb o n ew e r eo b t a i n e df r o me a c h
block using a 40  oil objective with identical scaling, scan
speed, and detector gain (employing a setting that ensured
that there was no saturation of the fluorescence in any of the
osteocyte lacunae). Mean fluorescence intensity of each
lacunar wall was determined by drawing around the entirety
of the lacunae using the line-profile tool, and the distance to
the nearest labeled bone or vascular channel surface was
measured using AIM software. A total of 632 osteocyte
lacunae were analyzed (at least 64 per mouse). Mean
fluorescence intensities of osteocyte lacunar walls of two
control mice were used to correct for autofluorescence,
whereas the maximum background fluorescence measured
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osteocyte lacunae that were labeled with AF647-RIS.
Isolation of rabbit and human bone marrow cells
Bone marrow cells were isolated from the long bones of vehicle-,
FAM-RIS-, AF647-RIS-, or RIS-treated rabbits by scraping out the
marrow and mincing the bones, as described previously.
(22) The
use of human bone marrow was approved by the North East
Scotland Research Ethics Committee. Informed consent was
obtained for the collection of bone marrow from patients
undergoing total hip replacement surgery in accordance with
the Declaration of Helsinki. Bone marrow was obtained by
aspiration during surgery. Red blood cells were lysed using
PharmLyse (BD Biosciences, Oxford, UK).
Isolation of rabbit osteoclasts and monocytes from
bone marrow
Osteoclasts were isolated from rabbit bone marrow by using
anti-vitronectin receptor (anti-VNR) magnetic beads, as
described previously.
(23) In some experiments, the VNR-negative
fraction (osteoclast-depleted bone marrow cells) was further
separated by CD14 MACS magnetic beads (Miltenyi Biotec,
Surrey, UK) according to the manufacturer’s instructions with
minor modifications. To enhance the purity, 4 mL anti-CD14
magnetic beads were used instead of the recommended 20mL
per 10
7 cells. In addition, the positive (CD14
þ) fraction was
passed through a second MACS MS column to further enhance
purity. The purity was approximately 90%, as determined by flow
cytometric analysis of CD14 staining.
In vitro treatment of bone marrow cells with fluorescent
RIS analogues
ForinvitrotreatmentwithfluorescentBPs,rabbitorhumanbone
marrow cells were plated out at 5 10
5cells/mL in 24- or 48-well
plates in medium (RPMI1640 supplemented with 10% FCS, 2mM
glutamine, 100U/mL penicillin, and 100mg/mL streptomycin)
and left to settle for 2 hours. Cells then were treated with 0 to
1 mM FAM-RIS or AF647-RIS or with 10mg/mL FITC-dextran for
24 hours.
Flow cytometry and confocal microscopy
Fordetectingintracellularuptakeoffluorescent RISanaloguesby
osteoclasts in vivo, osteoclasts obtained by anti-VNR magnetic
bead isolation were resuspended in medium (a-MEM with 10%
FCS, 2mM glutamine, 100U/mL penicillin, and 100mg/mL
streptomycin). Cells were seeded onto glass coverslips in 48-well
plates and left to adhere for 4 hours. Cells were washed once in
PBS, counterstained with 1mg/mL TO-PRO-3 or sytox green, and
analyzed for intracellular FAM-RIS or AF647-RIS uptake on a Zeiss
LSM510 META system. For detecting intracellular uptake of
fluorescent RIS analogues or FITC-dextran by other cells, rabbit
or human bone marrow cells were stained with either FITC- or
APC-conjugated anti-CD14 antibodies (Miltenyi Biotech, Surrey,
UK) and analyzed on a FACSCalibur flow cytometer using
CellQuestPro software (BD Biosciences). Vehicle-treated cells
served as controls for background fluorescence. The mean
fluorescence intensity was determined by calculating geometric
mean fluorescence in the FL1 (FAM-RIS) or FL4 (AF647-RIS)
channels using CellQuestPro software. In some experiments,
CD14
high AF647-RIS
þ cells were sorted on a FACSDiVa (BD
Biosciences) to facilitate subsequent analysis by microscopy.
Cells then were cytospun onto slides and counterstained with
0.5mg/mLsytoxorangepriortoanalysisonaZeissLSM510META
system using AIM software (Carl Zeiss, Ltd.) for image acquisition
and analysis.
Detection of unprenylated Rap1A by Western blotting
Cells isolated by anti-VNR and/or anti-CD14 magnetic bead
separation were lysed in radioimmunoprecipitation assay buffer
[PBS containing 1% (v/v) nonidet P40, 0.1% (w/v) SDS, 0.5% (w/v)
sodium deoxycholate, and 1:100 Sigma protease inhibitor
cocktail]. Equal protein amounts then were electrophoresed
under reducing conditions on 12% polyacrylamide-SDS gels
(Criterion, Bio-Rad, Hemel Hempstead, UK) and transferred onto
polyvinyl difluoride membranes by semidry transfer. Blots were
incubated with a polyclonal goat anti-Rap1A antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) that binds with high
affinity to the unprenylated form of this small GTPase
(24) and a
rabbit monoclonal anti-Rap1 antibody (Cell Signaling Technol-
ogy, Danvers, MA, USA). Blots then were incubated with Alexa
Fluor 680- and IRDye800-conjugated secondary antibodies and
analyzed on a LI-COR Odyssey Infrared Imager (LI-COR
Biosciences).
Statistical analysis
Statistical analysis was carried out using two-way analysis of
variance and the Holm Sidak posttest using SigmaPlot software.
Results
The effects of RIS and fluorescent RIS analogues on HAP
crystal growth in vitro
Inorder tomimicbonemineral,CAP seedwasusedas amodelof
mature bone, which has been shown to contain 4% to 7%
carbonate by mass.
(21,25) Inhibition data for HAP growth on CAP
in the presence of fluorescent RIS analogues were compared
with unlabeled RIS in an in vitro HAP crystal growth assay, as
described previously.
(20) The HAP growth rates, corrected for
specific surface area (SSA¼60.870m
2/g) of the seed material,
were 5.57 10
 8 and 5.79 10
 8mol/m
2 per minute for AF647-
RIS and FAM-RIS, respectively, which is a 35.4% and 32.8%
inhibition compared with the growth rate of 8.62 10
 8mol/m
2
per minute of the control (Fig. 1). The inhibition achieved by
unlabeled RIS was 48.6% (growth rate 4.43 10
 8mol/m
2 per
minute; see Fig. 1).
Detection of AF647-RIS in bones and soft tissues
To assess the tissue distribution of fluorescently labeled RIS, the
tibia/femur, kidneys, liver, and spleen were dissected from
3month old MF1 mice that had been injected with AF647-RIS
(0.9mg/kg) either 1 or 7 days previously, and AF647-RIS was
detected using a LI-COR Odyssey Infrared Imager with a 680nm
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skeletal tissue, with the tibia/femur showing an approximately
100-fold higher average fluorescence intensity than control
(p<.001; Fig. 2A, B). AF647-RIS also was present in the kidneys,
although at much lower levels (average fluorescence intensity
approximately fourfold higher than control, p<.05), whereas no
significant accumulation in liver or spleen was detected (see
Fig. 2A, B). At 7 days after injection, AF647-RIS still was clearly
present in tibia/femur (p <.001 compared with control), whereas
AF647-RIS was not detectable in kidneys, liver, or spleen (see
Fig. 2C, D). AF647-RIS was not detectable in heart, lung, or eyes at
either time point (data not shown).
Binding of fluorescent RIS analogues to bone surfaces
in vivo
To examine in vivo localization of fluorescent RIS analogues
within bone in more detail, mouse tibiae were fixed in
formaldehyde and embedded in methyl methacrylate for
histologic analysis. Figure 3A shows an overview of FAM-RIS
labeling in a tibial cross section obtained by tile scanning on a
confocal microscope using a 20  objective. At the doses used,
virtually all bone surfaces adjacent to marrow space (trabecular
and cortical) showed FAM-RIS labeling. Following decalcification
of histologic sections, FAM-RIS labeling was no longer detected
(data not shown). Unconjugated fluorescein was not detectable
in histologic bone sections 24 hours after a single injection of
0.5mg/kg (data not shown). FAM-RIS labeling was observed only
along mineralized bone surfaces and was absent in hypertrophic
cartilage of the growth plate (indicated by arrow in Fig. 3A).
Similar findings were obtained with AF647-RIS.
Fig. 1. Growth of HAP on CAP in the presence of fluorescent RIS
analogues in vitro. Constant composition (CC) crystal growth experi-
ments were conducted in the presence of 1.0mM BP in order to assess
inhibitory potency of fluorescent RIS analogues (AF647-RIS, FAM-RIS)
compared with the parent molecule (RIS). Experimental conditions were
dHAP (relative supersaturation)¼9.00, pH 7.40 at 37.08C, and IS (ionic
strength)¼0.15M.
Fig. 2. Detection of AF647-RIS in whole tissues. Three month old mice were subcutaneously injected with AF647-RIS (0.9mg/kg), and the tibia, femur,
kidneys,liver,andspleenweredissectedeither1(A,B)or7daysafterinjection(C,D).Followingfixationovernight,bonesandorganswerescannedonaLI-
COR Odyssey Infrared Imager (LI-COR Biosciences) using a 680nm laser to detect the presence of AF647-RIS. (A, C) Near-infrared fluorescence images of
tissues from control and AF647-RIS-treated mice. (B, D) Average fluorescence intensity was quantified using Odyssey Version 2.1 software (LI-COR
Biosciences) and is expressed as mean SD (1 day: n¼4; 7 days: n¼3). a: p<.001 compared with control; b: p<.05 compared with control.
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channels and osteocytic lacunae
Detailed histologic analysis of mouse and rabbit long bones
24 hours after a single injection with fluorescent RIS analogues
revealed localization of FAM-RIS or AF647-RIS around vascular
channels and within osteocytic lacunae (see Fig. 3B–D).
Fluorescently labeled RIS also was observed frequently in
canaliculi, including those connecting the vascular channel to
the labeled osteocytic lacuna (see Fig. 3B). In addition, newly
forming osteocytic lacunae close to the bone surface showed
fluorescent RIS labeling (see Fig. 3C). Strikingly, osteocytic
lacunae in close proximity to vascular channels within the
cortical bone showed fluorescent RIS labeling, whereas
osteocytic lacunae further away from these channels showed
little or no labeling (see Fig. 3D). Quantification of AF647-RIS
labeling confirmed this, showing a clear inverse relationship
between the distance to the nearest bone or vascular channel
surface and the mean fluorescence intensity of the lacunar wall
(corrected for background fluorescence). In addition, the
percentage of positively labeled osteocytic lacunae decreased
with increasing distance (see Fig. 3E). There was no evidence of
internalization of FAM-RIS or AF647-RIS by osteocytes resident
within labeled lacunae.
Internalization of fluorescent RIS analogues by
osteoclasts in vivo
Our initial in vitro studies showed uptake of FAM-RIS from
dentine by resorbing osteoclasts.
(19) These studies demonstrated
accumulation of FAM-RIS within intracellular vesicles in
accordance with previous studies demonstrating endocytic
uptake of fluorescently labeled ALN by both macrophages and
resorbing osteoclasts.
(2,10) In this study, we investigated whether
intracellular uptake by osteoclasts was detectable in vivo
following a single injection with fluorescently labeled RIS.
Newborn rabbits were used for these experiments because we
demonstrated previously an accumulation of unprenylated
Rap1A (indicative of BP uptake) in osteoclasts in vivo following
a single injection of neonatal rabbits with RIS.
(23) Using this
model, FAM-RIS uptake was detected in histologic sections in a
small number of large, multinucleated cells close to the bone
surface (Fig. 4A). To further confirm uptake by osteoclasts in vivo,
osteoclasts wereisolated fromvehicle-,FAM-RIS-, andAF647-RIS-
treated rabbits by VNR magnetic bead separation and analyzed
by confocal microscopy. This clearly demonstrated intracellular
uptake of FAM-RIS and AF647-RIS into intracellular vesicles by
multinucleated VNR-positive osteoclasts (see Fig. 4B).
Inhibition of Rap1A prenylation by FAM-RIS in
osteoclasts in vivo
Since FAM-RIS inhibits the prenylation of Rap1A in J774.2
macrophage-like cells in vitro with similar potency to RIS,
(19) we
investigated the ability of FAM-RIS to inhibit Rap1A prenylation
in osteoclasts in vivo as a surrogate marker for cellular uptake.
Indeed, the unprenylated form of Rap1A was clearly detectable
in the VNR-positive (osteoclast) fraction followingtreatment with
FAM-RIS but was barely detectable in the VNR-negative fraction,
similar to unlabeled RIS (see Fig. 4C). AF647-RIS did not inhibit
Rap1A prenylation in J774.2 cells in vitro (data not shown) and
therefore was not tested for activity in vivo.
Uptake of fluorescent RIS analogues by bone marrow
cells in vitro
To investigate the possibility that non-osteoclast bone marrow
cells may internalize BP in vivo, we first examined the ability of
bone marrow cells to internalize fluorescent RIS analogues in in
vitro cultures. Rabbit bone marrow cells were treated with FAM-
RIS or AF647-RIS for 24 hours, and intracellular uptake of
Fig. 3. Histologic analysis of FAM-RIS and AF647-RIS binding to bone
surfaces in vivo. Three month old mice were injected with 0.5mg/kg (A)
or 1mg/kg (B, C) FAM-RIS or 0.9mg/kg AF647-RIS (D, E) and sacrificed
24 hours later. Tibiae were fixed in formaldehyde, embedded in methyl
methacrylate, and sectioned longitudinally (A–D) or cross-sectionally
through the midshaft (E). (A) Series of xy confocal microscopy images
of a2mmsection wereacquiredonan LSM710 METAsystemusinga 20 
objective. Scans were tiled using ZEN software to generate a high-
resolution overview image of FAM-RIS (black) labeling of bone surfaces.
Bar¼500mm. (B, C)2mm sections were counterstained with the nuclear
dye TO-PRO-3 and wheatgerm-agglutinin-Alexa Fluor 594 (C) prior to
analysis by confocal microscopy. Green: FAM-RIS; blue: TO-PRO-3; red:
wheatgerm-agglutinin-Alexa Fluor 594. Arrows indicate the presence of
FAM-RIS around osteocytes. Bar¼10mm. (D) xy image, acquired directly
from the MMA-embedded tibial block just below the block surface,
showing AF647-RIS labeling (black) within cortical bone near the peri-
osteal surface. Top image: Detector gain optimized for detection of
AF647-RIS around vascular channels (arrows). Bottom image: Detector
gain optimized for detection of AF647-RIS around osteocytic lacunae
surrounding the vascular channels (arrows). Bar¼50mm. (E) Quantifica-
tion of AF647-RIS labeling of osteocyte lacunar walls. The mean fluor-
escence intensity (corrected for tissue autofluorescence) and the
percentage of positively labeled osteocytic lacunae are expressed as a
function of the distance to the nearest labeled bone or vascular channel
surface (data binned into 10mm increments). Data shown are the mean
 SEM of four mice (0 to 70mm) or three mice (70 to 100mm).
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(Fig. 5A, B). AF647-RIS was more readily detectable than FAM-RIS,
with relative fluorescence units approximately 20-fold higher for
AF647-RIS than for FAM-RIS at all concentrations. Immunofluor-
escence staining for CD14 revealed that both FAM-RIS and
AF647-RIS were predominantly internalized by CD14
high mono-
cytes. At all concentrations, the average amount of FAM-RIS or
AF647-RIS internalized was higher in CD14
high cells than in
CD14
neg/low cells. Treatment with 10nM, 100nM, or 1 mM AF647-
RIS resulted in an increase in mean fluorescence intensity over
vehicle control of 16.8 4.7-fold for CD14
high versus 1.4 0.0-
fold for CD14
neg/low, 143.6 38.9-fold for CD14
high (p<.01)
versus 6.0 1.0-fold for CD14
neg/low, and 601.3 138.4-fold for
CD14
high (p<.001) versus 26.0 3.0-fold for CD14
neg/low,
respectively (mean SD, n¼3). Confocal microscopy analysis
(see Fig. 5C) confirmed intracellular uptake of AF647-RIS
preferentially by CD14
þ rabbit bone marrow cells. To determine
whether similar effects are seen with human bone marrow
cultures in vitro, bone marrow cells obtained from a patient
undergoing total hip replacement surgery were treated in vitro
with fluorescent RIS analogues for 24 hours, and cellular uptake
was determined by flow cytometry. Human bone marrow cells
demonstrated similar or even somewhat higher levels of BP
uptake compared with rabbit cells (see Fig. 5D), with 10nM,
100nM, or 1 mM AF647-RIS resulting in an increase in mean
fluorescence intensity over vehicle control of 65.4 8.4-fold for
CD14
high versus 2.0 0.1-fold for CD14
neg/low, 399.7 163.8-fold
for CD14
high (p<.001) versus 9.1 1.6-fold for CD14
neg/low,
and 686.9 69.8-fold for CD14
high (p<.001) versus 33.3 0.8-
fold for CD14
neg/low, respectively (mean SD, three replicates).
Finally, rabbit bone marrow cells treated with FITC-dextran, a
markeroffluid-phaseendocytosis,showedpreferentialuptakeof
FITC-dextran by CD14
high monocytes (see Fig. 5D), similar to the
uptake of fluorescently labeled RIS.
Uptake of fluorescent RIS analogues by bone marrow
cells in vivo
To investigate whether any bone marrow cells other than
osteoclasts showed detectable levels of uptake of fluorescent
RIS, newborn rabbits received a single injection with 0.9mg/kg
AF647-RIS (molar equivalent to 0.2mg/kg RIS) and after 24 hours
or7days,bonemarrowcellswereanalyzedforAF647-RISuptake.
AF647-RIS was used because this compound showed far greater
sensitivity for detecting intracellular uptake by rabbit bone
marrow cells in vitro than FAM-RIS (see Fig. 5B). Uptake in vivo
was detected in a subset of bone marrow cells by flow cytometry
(Fig.6A,B).ImmunostainingforCD14revealed thatthe majorcell
type that had internalized AF647-RIS were CD14
high monocytes,
similar to when bone marrow cells were treated with AF647-RIS
or FAM-RIS in vitro. The vast majority of CD14
high cells showed
detectable uptake of AF647-RIS in vivo. The increase in mean
fluorescence intensity over vehicle control of CD14
high cells after
24 hours was 18.5 11.3-fold (p<.05), which was significantly
more (p<.05) than the CD14
neg/low cells (increase in mean
fluorescence intensity over vehicle control: 2.5 0.6-fold).
AF647-RIS uptake by monocytes was still detectable at similar
levels 7 days after administration (see Fig. 5B), with an increase
in mean fluorescence intensity over vehicle control of 14.3 
4.3-fold (p¼.001) for CD14
high cells and 1.7 0.1-fold for
CD14
neg/low cells. Intracellular uptake of AF647-RIS by CD14
high
mononuclear cells in vivo was confirmed by fluorescence-
activated cell sorting of AF647-RIS
þCD14
high cells followed by
confocal microscopic analysis, demonstrating the presence of
AF647-RIS within CD14-labeled mononuclear cells (see Fig. 6C).
Inhibition of Rap1A prenylation in rabbit bone marrow
cells in vivo in response to RIS
To determine whether efficient uptake of fluorescently labeled
RIS by bone marrow monocytes in vivo correlates with an
accumulation of unprenylated Rap1A inthis cell type inresponse
toRIS,newborn rabbits weretreatedwith RISorvehicle only, and
bone marrow cells were isolated 24 hours later. Osteoclasts were
isolated first from the bone marrow cells based on VNR
expression, followed by separation of the osteoclast-depleted
bonemarrowcellsintomonocytesandnon-monocytesbasedon
Fig. 4. FAM-RIS and AF647-RIS uptake by rabbit osteoclasts in vivo.
Newborn rabbits were injected with 0.5mg/kg FAM-RIS or 0.9mg/kg
AF647-RIS (A, B) or with 3mg/kg FAM-RIS or the molar equivalent dose of
1.2mg/kg RIS (C) or vehicle and sacrificed 24 hours later. (A) Confocal
microscopic imageof a longitudinal section through an ulna from a FAM-
RIS-treated (green) rabbit counterstained with the nuclear dye TO-PRO-3
(blue). Tissue autofluorescence shown in red channel. Bar¼10mm. (B, C)
Bonemarrowcellswere isolatedfromthe longbones by scrapingout the
marrow, and osteoclasts were isolated using anti-VNR magnetic beads.
(B) Isolatedosteoclasts were left to adhere on glass coverslips for 4 hours,
fixed in formaldehyde, and counterstained with TO-PRO-3 (FAM-RIS and
vehicle) or sytox green (AF647-RIS) prior to analysis of intracellular drug
uptake using confocal microscopy. i: Osteoclast from vehicle-treated
rabbit. ii: Osteoclast from FAM-RIS-treated rabbit. Green: FAM-RIS; blue:
TO-PRO-3; red: Magnetic bead autofluorescence. iii: Osteoclast from
AF647-RIS-treated rabbit. Green: AF647-RIS; blue: sytox green.
Bar¼10mm. (C) Isolated VNR-positive and VNR-negative cells were lysed
and analyzed for the presence of unprenylated Rap1A by Western
blotting using an antibody that binds with high affinity to the unpre-
nylated form of the protein (uRap1A) and an antibody that detects total
Rap1.
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scraping out the marrow (A–C, E) or isolated from a bone marrow aspirate of a patient undergoing total hip replacement surgery (D) were treated in vitro
with vehicle only; with 10nM, 100nM, or 1mM AF647-RIS (A–D) or FAM-RIS (A, B); or with 10mg/mL FITC-dextran (E) for 24 hours. Cells then were stained
with anti-CD14-APC for FAM-RIS- and FITC-dextran-treated cells or with anti-CD14-FITC for AF647-RIS-treated cells. (A) Representative flow cytometry
profiles showing AF647-RIS uptake. (B) Quantification of flow cytometry results of rabbit bone marrow cells, shown as mean fluorescence intensity
expressed as mean SD (n¼3). (C) Confocal microscopic image (1 mm optical section) showing intracellular uptake of AF647-RIS by CD14
þ cells.
Bar¼10mm. (D) Quantification of AF647-RIS uptake by human bone marrow cells by flow cytometry. Results are shown as mean fluorescence intensity
andexpressed as mean SD (threereplicates).(E) Quantification of flow cytometryanalysis of FITC-dextran uptake, shownas mean fluorescence intensity
and expressed as mean SD (n¼3). a: p<.001; b: p<.01 versus control and versus respective CD14
neg/low cells; c: p<.05 versus control.
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was clearly detectable in the osteoclast and monocyte fractions
by Western blotting, whereas no unprenylated Rap1A was
detected in the non-monocyte fraction or in cells isolated from
rabbits treated with vehicle only (see Fig. 6D).
Discussion
We report here the use of novel fluorescent RIS analogues to
study both the localization and cellular uptake of BP in vivo. We
have used RIS conjugated to two different fluorophores, FAM
andAF647,employinganewlydevelopedmethodthatallowsfor
stable conjugation to RIS.
(19) Labeling with FAM offers the
advantage that it emits in the visual spectrum, greatly facilitating
analysis of histologic sections and microscopic analysis of
intracellular uptake. Moreover, FAM-RIS retains the ability to
inhibit protein prenylation both in vitro
(19) and in vivo in
osteoclasts (this study), suggesting that it closely mimics the
pharmacologic characteristics of RIS in vivo. On the other hand,
near-infrared imaging using AF647-RIS offers the advantages of
high tissue penetration together with minimal tissue autofluor-
escence, enabling deeper imaging into bones embedded in
methyl methacrylate and providing a higher sensitivity of
detection than FAM-RIS. The latter property is crucial for
permitting the study of cellular uptake of AF647-RIS in a
clinically relevant dose range. AF647-RIS also has the advantage
over the near-infrared pamidronate analogues Osteosense680
Fig. 6. AF647-RIS and RIS uptake by rabbit bone marrow cells in vivo. Newborn rabbits were subcutaneously injected with 0.9mg/kg AF647-RIS (A–C)o r
5mg/kg RIS (D) or vehicle and sacrificed 24 houre (A–D) or 7 days later (B). Bone marrow cells then were isolated from the long bones by scraping out the
marrow.(A–C)Cellswerestainedwithanti-CD14-FITCandanalyzedbyflowcytometryandconfocalmicroscopy.(A)Representativeflowcytometryprofiles
showing detectable uptake of AF647-RIS by some bone marrow cells in vivo, a subset of which is CD14
high.( B) Quantification of flow cytometry results of
bone marrow cells analyzed 24 hours (left) and 7 days (right) after administration of AF647-RIS. Results are shown as mean fluorescence intensity and
expressedasmean SD(n¼3).a:p .01; b:p<0.001versuscontrolandversusCD14
neg/lowcells.(C)1mmopticalsectionshowingAF647-RISuptakebya
CD14
þ cell analyzed followingflow cytometricsorting of CD14
high AF647-RIS
þ cells (green: AF647-RIS;blue:CD14-FITC;red: sytox orange; bar¼10mm). (D)
Osteoclasts were isolated using anti-VNR magnetic bead separation, followed by isolation of monocytes from the VNR-negative fraction by anti-CD14
magnetic beads. Cells were lysed, and unprenylated Rap1A and total Rap1 were detected by SDS-PAGE and Western blotting. Red: Unprenylated Rap1A
(uRap1A); green: Rap1.
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(17,18) of being readily detectable on standard
flow cytometers and confocal microscopes equipped with a
633nm laser.
We showed previously, by measurement of the retention time
on hydroxyapatite columns, that the affinity of FAM-RIS for bone
mineral in vitro is comparable, albeit somewhat lower, to that of
unlabeled RIS.
(19) In this study, these findings have been
confirmed using an in vitro HAP crystal growth assay as a
model to determine the relative affinity for bone mineral,
(20)
which demonstrated that both FAM-RIS and AF647-RIS sig-
nificantly inhibited HAP crystal growth. Furthermore, AF647-RIS
was retained in skeletal tissue up to at least 1week following
administration. AF647-RIS also was detectable in kidneys 1 day
after administration, consistent with urinary excretion of BP that
is not taken up by skeletal tissue following administration.
(26)
After 1week, AF647-RIS was no longer detectable in the kidneys,
and the liver and spleen did not show significant retention of
AF647-RIS at either time point. These findings show that the
tissue distribution of AF647-RIS is characteristic of BP drugs,
(1,26)
suggesting that the pharmacokinetic properties are predomi-
nantly conferred by the two phosphonate groups, with little
influence of the conjugated side chain.
Histologicanalysisrevealedthatbothfluorescentanaloguesof
RIS bound to bone surfaces. The absence of FAM-RIS in
nonmineralized cartilage of the growth plate, together with
the loss of FAM-RIS labeling of bone surfaces following
decalcification and the lack of retention of unconjugated
fluorescein in bone, confirmed that FAM-RIS was bound to
bone mineral in vivo through the BP moiety of the molecule.
More detailed analysis of the distribution of fluorescent RIS
analogues on bone surfaces revealed its presence in osteocytic
lacunae. In particular, fluorescently labeled RIS was present in
lacunar walls close to the bone surface, surrounding osteocytes
that appeared to be in the process of becoming entombed, and
in lacunae close to vascular channels within cortical bone.
Moreover, a clear inverse relationship was found between the
distance of the lacuna to the nearest bone or vascular channel
surface and the extent of AF647-RIS labeling in terms of both the
percentage of positively labeled osteocytic lacunae at a given
distance and the mean intensity of labeling. No uptake of BP by
osteocytes was observed, although we have found that confocal
imaging of these specimens is a relatively insensitive method for
assessing intracellular fluorescence (compared with flow
cytometry, for example), so we cannot exclude the possibility
of intracellular uptake. However, irrespective of cellular uptake,
the presence of BP lining the walls of osteocytic lacunae adds
credence to previous studies demonstrating prosurvival effects
of BPs on osteocytes in vivo mediated through an extracellular
mechanism.
(27,28) It has been proposed that BPs stimulate the
opening of connexin-43 hemichannels and intracellular calcium
influx, followed by the rapid activation of extracellular signal-
regulated kinases.
(29,30) These previous findings raised the
possibility that potential interactions of BPs with osteocytes in
vivo may contribute to antifracture efficacy, independent of the
classic antiresorptive actions via osteoclasts.
(1) Interestingly, our
findings that fluorescent RIS analogues label predominantly
osteocyte lacunae that are close to bone surfaces exposed to the
circulation (i.e., the marrow cavity or vascular channels) indicate
that only a limited proportion of osteocytes may be exposed to
substantial amounts of BP in vivo. It is possible, though, that with
repeateddosingandincreasingtime,anincreasingproportionof
the osteocytic network may become coated with BP. Further-
more, since the antiapoptotic effects of N-BPs occur at low
(nanomolar) concentrations,
(27,29) it is possible that the number
of osteocytes that are exposed to such concentrations of BP in
vivo may be higher than we can detect by fluorescence
microscopy. Nevertheless, our findings that the fluorescent RIS
analogues were not evenly distributed throughout the canali-
cular network raises the possibility that the distribution of
different BPs within this canalicular network may vary and may
be influenced by their affinity for bone mineral. This remains to
be further investigated.
Analysis of intracellular uptake of fluorescent RIS analogues
demonstrated that CD14
high monocytes internalized relatively
large amounts of BP both in vitro and in vivo compared with
other bone marrow cell populations. This is consistent with our
previous findings that BPs, owing to their negatively charged
phosphonate groups, largely depend on fluid-phase endocytosis
for their cellular uptake
(10) and that highly endocytic cell types
suchasmacrophagesandmonocytesdemonstratemuchgreater
levels of intracellular uptake and are more sensitive to BP than
less endocytic cell types such as lymphocytes, osteoblasts, and
breast cancer cells in vitro.
(2,12) Consistent with this, CD14
high
bone marrow monocytes showed the highest levels of uptake of
FITC-dextran, a marker of fluid-phase endocytosis. Preferential
uptake of fluorescently labeled RIS by bone marrow monocytes
also correlated with selective accumulation of unprenylated
Rap1A (a surrogate marker for inhibition of FPP synthase) in
monocytes, as well as osteoclasts, in response to treatment with
RIS in vivo, demonstrating the potential relevance of selective
uptake of BP by monocytes in vivo. Intracellular levels of AF647-
RIS in the monocyte population were maintained for at least
7 days after administration. This suggests that BP administration
may have prolonged effects on the population of monocytes in
the bone marrow. This finding also raises the possibility that the
uptake of BP by monocytes in the bone marrow may be a
continual process, perhaps secondary to the release of BP from
the bone surface during the resorptive process, as was
demonstrated previously in in vitro studies.
(2) However, it is at
present unclear whether the AF647-RIS-labeled monocytes
identified at 7 days after administration are a separate
population from those present after24 hours. Thus the relevance
of these in vitro findings needs to be further investigated in vivo.
Interestingly, an additional minor subset of bone marrow cells
that did not express high levels of CD14 also showed detectable
uptake of AF647-RIS in vivo, although the degree of uptake was
somewhat lower than in CD14
high monocytes. While the identity
of these cells remains to be determined, a minor subset of
CD14
neg/low bone marrow cells also showed more than average
uptake following treatment of bone marrow cells with AF647-RIS
in vitro in the absence of a mineralized surface, suggesting that
this population may comprise other highly endocytic cell types
present in the bone marrow, such as immature monocytes not
(yet) expressing high levels of CD14.
Taken together, these results demonstrate for the first time
that non-osteoclast cells are capable of internalizing BP in vivo.
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uptake in vivo suggests that uptake in vivo is predominantly
determined by the endocytic activity of cells rather than by their
localization within bone, although spatial distribution in vivo
may to some extent influence the amount of BP uptake of
individual cells. In particular, cells in close proximity to resorbing
osteoclasts may be exposed to BP released from the bone
surface during the resorption process that becomes available for
intracellular uptake. In support of this, we recently showed in in
vitro studies that J774 macrophages show limited BP uptake
from the surface of dentine, but this is increased in the presence
of resorbing osteoclasts.
(2) This could be a contributing factor in
determining in vivo cellular uptake of BP by monocytes.
Sato and colleagues calculated from in vitro bone resorption
assays that the concentration of ALN achieved in the resorption
lacunae of osteoclasts would be 0.1 to 1mM if 50% of the
mineral-bound ALN is released during the resorption process.
(7)
However, no data currently exist on in vivo concentrations of BP
within the bone marrow. The results presented here show that
following a single subcutaneous injection with 0.9mg/kg AF647-
RIS (molar equivalent to  0.2mg/kg RIS) in newborn rabbits,
cellular uptake of BP by bone marrow cells, as measured by flow
cytometry, is comparable with the extent of cellular uptake by
bone marrow cells treated with 10 to 100nM AF647-RIS for 24
hours in vitro (in the absence of a mineral surface). It is therefore
tempting to suggest, based on these findings, that the
concentration of BP achieved in the bone marrow microenvir-
onment following a single dose with 0.2mg/kg is somewhere in
the range of 10 to 100nM over a 24 hour period. RIS and ALN are
typically administered orally at a weekly dose of 35 or 70mg,
whereas cancer patients generally receive infusions of 4mg
zoledronic acid once every 3 months or up to 90mg
pamidronate every 3 to 4 weeks. While it is difficult to draw
direct comparisons between administration to animals and the
clinical dose in humans, especially with regard to the orally
administered BPs, a dose of 0.2mg/kg BP in mice appears to be
within the clinically relevant range.
The preferential uptake of BP by monocytes, both in vitro and
in vivo, may contribute to or help explain some of the actions of
BPs. Most notably, it has become clear in recent years that direct
effects of BPs on circulating monocytes appear to be responsible
for the activation of peripheral blood Vg9Vd2 T cells by N-BPs,
which can lead to the development of an acute-phase
response.
(12–16) This clearly indicates that in patients on
intravenous BP therapy, BPs reach a sufficiently high concentra-
tion in the circulation to directly affect these cells. Additionally,
direct effects of BPs on monocytes/macrophages also may be
responsible for (some of) the antitumor activity of these drugs.
One possible mechanism in humans is through activation of
Vg9Vd2 T cells, which possess potent antitumoral activity.
(31) In
addition, some of the antitumor effects of BPs in both humans
and animals may be explained by effects on tumor-associated
macrophages (TAMs). TAMs can have various protumoral
functions, including promotion of angiogenesis, matrix remodel-
ing (facilitating the invasive process), and suppression of
adaptive antitumor immunity.
(32) Previous studies showed a
dramatic decrease in the number of TAMs in various murine
models of cancer following treatment with N-BPs, and this was
associated with a decrease in tumor vasculature.
(33–35) Finally,
previous studies have suggested that BPs may act not only by
inhibiting the activity of mature osteoclasts but also by
decreasing osteoclastogenesis.
(36–38) Our findings suggest that
effects on osteoclast formation might be explained by BP uptake
into monocytic precursors of osteoclasts in the bone marrow.
In conclusion, fluorescent RIS analogues were found to bind to
bone surfaces with minimal retention in nonmineralized tissues
(kidneys, liver, spleen) and showed uptake by osteoclasts in vivo.
The fluorescent RIS analogues labeled osteocytic lacunae either
close to the bone surface or close to vascular channels within
cortical bone. Since BPs have been shown to promote osteocyte
survival through an extracellular effect,
(27–30) it is possible that BP
present in the osteocyte lacunae is sufficient to directly maintain
the survival of these cells in vivo. However, further studies would
be required to confirm this. Furthermore, in addition to
intracellular uptake by osteoclasts, bone marrow monocytes
internalized relatively large amounts of fluorescently labeled RIS
in vivo, suggesting that monocytes also may be directly affected
by BPs.
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